Doctors from only four medical specialties will be able to write prescriptions for injectable drugs that are used to treat ...

Eli Lilly announces positive results from phase 3 ATTAIN-1 trial of orforglipron, an oral GLP-1 receptor agonist to treat obesity: Indianapolis Friday, August 8, 2025, 09:00 Hrs [ ...

In July 2025 alone, Wegovy clocked Rs 7 crore in sales with around 5,000 injections, while Mounjaro posted Rs 47 crore in ...

Explores Behemoth Labz GLP‑1 nasal formulation's structural design, analytic insights, and intranasal incretin research relevance in preclinical metabolic ...

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

Shares of Eli Lilly & Co. suffered their biggest selloff in 26 years on Thursday, after the drug giant disclosed late-stage trial data for its weight-loss pill that fell well short of expectations.

ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the ...

In Oklahoma, approximately 405,800 adults have diabetes, and every year, about 26,000 adults in the state are diagnosed with ...

Orforglipron showed clinically meaningful results at 72 weeks, after three doses, in a pool of more than 3000 adults.

Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...

An experimental once-daily pill to treat obesity can help people lose a significant amount of weight, according to new data ...